Skip to Content Contact Us
About Img

About Amendis

Providing a solution to a critical unmet need in
the personalized treatment of Oral Cavity Cancer.

 

Unmet need in personalized medicine.

Worldwide, head and neck cancers are the sixth leading cancer group by incidence, with approximately 630,000 new patients diagnosed annually, resulting in more than 350,000 deaths every year. Oral cancer is one of the most common types of tumors in the head and neck, while squamous cell carcinomas (SCCs) constitute more than 90% of all oral cancer. Oral SCCs are invasive lesions with a significant recurrence rate that frequently metastasize, where tongue tumors have the greatest tendency of all oral SCCs for metastasis to the neck.

 

Img08
Img07
38%

of all HNSCC tumors are located in
the oral cavity area

Img07
50%

Overall five year survival rate

Img07
70%

of elective neck dissections following diagnosis, turn out to have been unnecessary as they are performed without evidence of lymph nodes metastases.

Cervical lymph node metastasis is the single most important prognostic factor in oral cancer, and survival chances are reduced by 50% when compared to those with similar primary tumors without neck metastases. The stage of the oral cancer is determined using the TNM staging system, where T describes the size and depth of the primary tumor, N whether the cancer has spread to the lymph nodes, and M whether the cancer has spread to another part of the body.

Amendis’s solution provides a much more accurate prediction of the future development of head and neck cancer metastasis, and will thus prevent as much as 40% of unnecessary neck surgeries.

Amendis Key Roles

עמית מעודכן
Dr. Cohen is a molecular biologist with expertise in the field of RNA, and is also registered dietitian. His research has focused on the role of microRNA in the development of cancer. Since 2012 Dr. Cohen has been analyzing cancer gene expression data in collaboration with Dr. Yoav Smith from the Hebrew University of Jerusalem.
× Dr. Cohen is a molecular biologist with expertise in the field of RNA, and is also registered dietitian. His research has focused on the role of microRNA in the development of cancer. Since 2012 Dr. Cohen has been analyzing cancer gene expression data in collaboration with Dr. Yoav Smith from the Hebrew University of Jerusalem.
יואב מעודכן
Dr. Smith is a graduate of the Technion-Israel Institute of Technology (BSEE), the University of Pittsburgh (MSEE), and the Hebrew University of Jerusalem Medical School (Ph.D.). He is the manager of the Genomic Data Analysis Unit at the Hebrew University of Jerusalem Medical School, and has published more than 50 scientific articles, holds 8 patents and lectures in various fields including data visualization and analysis.
× Dr. Smith is a graduate of the Technion-Israel Institute of Technology (BSEE), the University of Pittsburgh (MSEE), and the Hebrew University of Jerusalem Medical School (Ph.D.). He is the manager of the Genomic Data Analysis Unit at the Hebrew University of Jerusalem Medical School, and has published more than 50 scientific articles, holds 8 patents and lectures in various fields including data visualization and analysis.
ניר מעודכן
Dr. Hirshoren is a Senior Physician in the Department of Ear, Nose, & Throat at the Hadassah Medical Center, Jerusalem, and a specialist in oncological head and neck surgery. He has published numerous articles related to his fields.
× Dr. Hirshoren is a Senior Physician in the Department of Ear, Nose, & Throat at the Hadassah Medical Center, Jerusalem, and a specialist in oncological head and neck surgery. He has published numerous articles related to his fields.
Nir Hirshoren M.D.
Medical Director
Read More
שמיר מעודכן
Mr. Kaminsky is a lawyer and a successful entrepreneur in the Biomedical Field. He was the CEO of Leumit Health Care Services, an Israeli HMO, and is an expert in medical insurance and international marketing.
× Mr. Kaminsky is a lawyer and a successful entrepreneur in the Biomedical Field. He was the CEO of Leumit Health Care Services, an Israeli HMO, and is an expert in medical insurance and international marketing.
גיל מעודכן
Highly experienced, for 20 years Dr. Pogozelich has been leading successful technology startups. He now specializes in the development, integration and commercialization of Life Science technologies, with emphasis on the field of personalized medicine. He previously specialized in the management of complex development teams in algorithms and engineering, and has registered and co-registered a number of patents.
× Highly experienced, for 20 years Dr. Pogozelich has been leading successful technology startups. He now specializes in the development, integration and commercialization of Life Science technologies, with emphasis on the field of personalized medicine. He previously specialized in the management of complex development teams in algorithms and engineering, and has registered and co-registered a number of patents.
Back top top